Your Child’s Care Team | NYU Langone Health
Meet the members of the care team at Hassenfeld Children’s Hospital at NYU Langone.
Your Child's ECMO Treatment | NYU Langone Health
At Hassenfeld Children’s Hospital at NYU Langone, we provide support while your child is receiving extracorporeal membrane oxygenation (ECMO).
Your Child’s Visit | NYU Langone Health
We help you prepare for your child’s visit to Hassenfeld Children’s Hospital at NYU Langone.
Your Emergency Care Visit | NYU Langone Health
NYU Langone offers information about what to expect during your emergency care visit in Manhattan, Brooklyn, or Long Island.
Your First Visit to Perlmutter Cancer Center | NYU Langone Health
We work with you to ensure that your first visit to Perlmutter Cancer Center is as streamlined as possible.
Your Visit to Stephen D. Hassenfeld Children's Center for Cancer & Blood Disorders | NYU Langone Health
Get information on what to expect from your first visit to NYU Langone’s Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders.
Youth & Adolescent Services at Family Health Centers at NYU Langone | NYU Langone Health
Youth and adolescent services are provided through Family Health Centers at NYU Langone’s Community-Based Programs.
Zenith p-Branch Pivotal Study
This clinical investigation is intended to evaluate the safety and effectiveness of the Zenith® p-Branch™ in combination with Atrium iCAST™ covered stents for the treatment of pararenal or juxtarenal aortic aneurysms. The primary safety and effectiveness endpoint is treatment success at 12 months. This prospective, non-randomized, multicenter clinical investigation will enroll up to 82 patients to receive the Zenith® p-Branch™ at up to 30 clinical sites (maximum of 20 patients per site). Patient enrollment is expected to be completed within 2.5 years of study initiation. Follow-up data will be collected for 5 years post-procedure
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease chronic kidney disease and systemic inflammation
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
10852_elto_question_fhp2.PDF
Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Instructions The questions on the back page ...